Natco Pharma Ltd
NSE:NATCOPHARM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
801.75
1 592.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Natco Pharma Ltd
Natco Pharma Ltd
Total Receivables
Natco Pharma Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Natco Pharma Ltd
NSE:NATCOPHARM
|
Total Receivables
₹14.5B
|
CAGR 3-Years
45%
|
CAGR 5-Years
21%
|
CAGR 10-Years
19%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Receivables
₹84.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Receivables
₹55.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Receivables
₹129.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Receivables
₹17.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Total Receivables
₹9.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Natco Pharma Ltd
Glance View
Nestled in the bustling business corridors of Hyderabad, India, Natco Pharma Ltd. has cultivated a strong presence in the pharmaceutical industry over the decades. Founded in 1981, the company initially ventured into the local market, gradually establishing itself as a critical player through specialization in complex chemistry and niche therapeutic sectors. The company's primary focus is on the development and manufacturing of generic drugs, specifically in the oncology and neurology segments. In these high-stakes areas, Natco leverages its robust research and development capabilities to produce affordable alternatives to expensive branded medications, thereby ensuring access to critical treatments for broader populations. Natco Pharma's business acumen extends beyond merely producing generics. It is adept at capitalizing on patent expirations, quickly launching generics and biosimilars in both domestic and international markets. The company has strategically focused operations in markets such as the United States and Europe, where it partners with local distributors to reach end-users. Through a combination of manufacturing efficiencies and strategic partnerships, Natco is able to maintain competitive pricing, thus enhancing its market penetration and revenue generation. Its integrated business model, combining in-house R&D, manufacturing, and distribution, ensures that Natco remains a formidable player, bridging the gap between complex pharmaceuticals and cost-effective healthcare solutions.
See Also
What is Natco Pharma Ltd's Total Receivables?
Total Receivables
14.5B
INR
Based on the financial report for Sep 30, 2024, Natco Pharma Ltd's Total Receivables amounts to 14.5B INR.
What is Natco Pharma Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
19%
Over the last year, the Total Receivables growth was 28%. The average annual Total Receivables growth rates for Natco Pharma Ltd have been 45% over the past three years , 21% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
